Use of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Patients with Metastatic Colorectal Cancer: A Single Center Experience

Authors : Gülçin ŞAHİNGÖZ ERDAL, İlkay GÜLTÜRK, Aykut ÖZMEN, Seher Yıldız TACAR, Mesut YILMAZ, Deniz TURAL

Pages : 1112-1119

View : 34 | Download : 7

Publication Date : 2022-10-29

Article Type : Research Paper

Abstract :Introduction: Despite all the advances in therapeutic modalities, Colorectal Cancerinsert ignore into journalissuearticles values(CRC); continues to be the fourth most common cause of cancer-related deaths. The aim of this study was to share our experiences regarding the usage rates of monoclonal antibodiesinsert ignore into journalissuearticles values(mAbs); insert ignore into journalissuearticles values(such as Bevacizumab, Cetuximab, and Panitumumab);, overall survivalinsert ignore into journalissuearticles values(OS); and progression-free survivalinsert ignore into journalissuearticles values(PFS); in patients with metastaticCRCinsert ignore into journalissuearticles values(mCRC);. Material metod: This retrospective study included 210 patients with mCRC who were followed up in our hospital\`s oncology clinic between January 2010 and October 2020 and who received mAb treatment, regardless of their stage at the time of diagnosis. Results: Fifty-twoinsert ignore into journalissuearticles values(24.8%); of the patients received a treatment regimen with Cetuximab and 46 with Panitumumab mAb, 29 patientsinsert ignore into journalissuearticles values(17.8%); received Cetuximab and Bevacizumab mAb treatment at different times, and 22 patients received Panitumumab and Bevacizumab mAb treatment, 112 of the patients received only Bevacizumab treatment. Panitumumab and Cetuximab mAb treatment was mostly taken in the 1st linesinsert ignore into journalissuearticles values(69.6%, 76.9%, respectively);. A statistically significant difference was found between the OSs of the cases according to the mAb treatment receivedinsert ignore into journalissuearticles values(p=0.001);. Administration of Panitumumab and Cetuximab mAb in the 1st or 2nd series didn’t make a significant difference to PFS. Discussion: The distribution of Panitumumab and Cetuximab mAb treatments was found to be balanced. They were preferred to give it in the first line. Patients who received anti EGFR mAb treatment had longer OS and PFS duration than those who received anti VEGF mAb only. It can be said that taking anti EGFR mAb treatmentinsert ignore into journalissuearticles values(being KRAS WT); has a positive effect on prognosis.
Keywords : colon cancer, bevacizumab, cetuximab, panitimumab

ORIGINAL ARTICLE URL